Extends ongoing work focused on advancing R&D innovation and improving clinical trials
NEW YORK; October 1, 2015 – Accenture (NYSE:ACN) has been selected by TransCelerate BioPharma Inc., a non-profit organization focused on advancing innovation in R&D for the biopharmaceutical industry, to support its Placebo and Standard of Care initiative (PSoC). The PSoC initiative has been established to maximize the value of historic clinical data collected during clinical trials, and is the first cross-therapeutic, multi-sponsor clinical data sharing initiative of its kind in life sciences designed to improve trial design and safety surveillance.
Accenture will help TransCelerate member companies better aggregate, share, and use clinical data collected in the placebo and standard-of-care arms of clinical trials. This agreement aims to optimize the use and sharing of clinical data by ensuring it is compliant with the standards set by the Clinical Data Interchange Standards Consortium. Insights gained from the combined data have the potential to reduce both the time spent on, and number of patients involved in clinical trials; improve the patient experience; and enable a better understanding of diseases.
Ed Bowen, Senior Director, Translational and Bioinformatics at Pfizer and the lead for this initiative, said: “Having access to this data among TransCelerate member companies has the potential to be a powerful tool for clinical research. This initiative is representative of TransCelerate’s overall mission: to collaborate across the global R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of medicines.”
“Today the industry struggles to maximize the use of historically collected clinical data to enhance prospective study design, interpret safety signals and inform patient recruitment strategies,” said Kevin Julian, managing director, Accenture Accelerated R&D Services, Life Sciences. “Working with TransCelerate we aim to provide a solution that helps strengthen these capabilities quickly and efficiently for the industry.”
Accenture was chosen by TransCelerate in 2012 to provide program management and change management services for the development and adoption of the TransCelerate portfolio of initiatives. In March 2015 Accenture also delivered a project to achieve an automated solution that simplifies the process of sourcing comparator drugs for TransCelerate’s Comparator Network initiative.
“Accenture is an important collaborator with TransCelerate,” said Dalvir Gill, CEO of TransCelerate BioPharma Inc. “Accenture’s deep expertise in life sciences, technology, and clinical data-related services will be instrumental in delivering a data sharing solution. This new project builds on the multi-year relationship between Accenture and TransCelerate.”
About TransCelerate BioPharma Inc.
TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by accelerating and simplifying the research and development (R&D) of innovative new therapies. The organization’s mission is to collaborate across the global R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of medicines. TransCelerate evolved from discussions at various forums for executive R&D leadership to debate current issues facing the industry and examine solutions for addressing agreed-upon common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Amgen, Astellas Pharma Inc., Biogen, EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Medgenics, Inc., Merck & Co., Inc., Novo Nordisk, Shionogi & Co., Ltd. and UCB.
Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research and Development operations. Executive offices are located in Philadelphia, PA. For more information, please visit http://www.transceleratebiopharmainc.com/.
Accenture is a global management consulting, technology services and outsourcing company, with more than 358,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$31.0 billion for the fiscal year ended Aug. 31, 2015. Its home page is www.accenture.com.
+ 1 312 693 5992
+ 1 212 584 5470